Holen Sie sich die Stockscreener-App
3.94
10.67%
0.38
Handel nachbörslich:
3.91
-0.03
-0.76%
Lixte Biotechnology Holdings Inc Aktie (LIXT) Neueste Nachrichten
Can Lixte Biotechnology Holdings Inc. stock continue upward trendEarnings Forecast Updates & High Yield Trading Growth - ulpravda.ru
Lixte Biotechnology Holdings (NASDAQ: LIXT) Announces $4.3M Registered Direct Offering Priced at Market - Digital Journal
LIXTE Biotechnology Advances Novel Cancer Treatment Platform Through Clinical Trials and Strategic Moves - citybuzz -
Lixte Biotechnology Holdings Secures $4.3 Million in Registered Direct Offering to Advance Cancer Drug Development - citybuzz -
Will Lixte Biotechnology Holdings Inc. (8640) stock deliver compounding returns2026 world cup usa national team quarterfinals young talents transition play winner prediction breakdown - ulpravda.ru
Aug Decliners: Why Lixte Biotechnology Holdings Inc. (8640) stock is listed among top recommendationsInsider Buying & Weekly Momentum Stock Picks - moha.gov.vn
What analysts say about Lixte Biotechnology Holdings Inc 8640 stockCandlestick Trading Patterns & High Return Stock Picks - earlytimes.in
What analysts say about SBCWW stockTechnical Breakout Signals & Free Wealth Planning Blueprints - earlytimes.in
Should You Add Aster DM Healthcare Limited Stock to Your Portfolio NowResistance Breakout Alerts & Minimal Capital Growth - earlytimes.in
Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuationAnalyst Upgrades & Free High Yield Investment Strategies - bollywoodhelpline.com
Lixte Simplifies Capital Structure via Share Exchange Deal - TipRanks
Price Clustering Detected in Anupam Finserv Limited StockLong-Term Investment Plans & Low Risk High Yield - bollywoodhelpline.com
Will Lixte Biotechnology Holdings Inc. stock see insider buyingTake Profit Strategies & Low Entry Investment Portfolio - Bollywood Helpline
LIXTE expands clinical trial for ovarian cancer treatment By Investing.com - Investing.com Australia
Lixte Expands LB-100 Ovarian Cancer Trial Collaboration - TipRanks
Lixte expands LB-100 ovarian cancer trial collaboration - MSN
Key facts: Lixte Biotechnology secures $4.3M funding; expands cancer collaboration - TradingView — Track All Markets
LIXTE expands clinical trial for ovarian cancer treatment - Investing.com
Lixte Biotechnology Holdings expands collaboration with University of Texas MD Anderson Cancer Center & GSK for LB-100 - marketscreener.com
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - InvestorNews
Experimental ovarian cancer trial doubles the number of patients it will enroll - Stock Titan
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering - Investing.com Nigeria
Lixte Biotechnology Announces New Registered Direct Offering - TipRanks
Lixte Biotechnology Signs Multiple Material Agreements - TradingView — Track All Markets
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering By Investing.com - Investing.com South Africa
Lixte Biotechnology stock falls after $4.3 million direct offering - Investing.com
Lixte Biotechnology stock falls after $4.3 million direct offering By Investing.com - Investing.com Canada
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering - The Manila Times
Will Lixte Biotechnology Holdings Inc. stock keep outperforming rivalsJuly 2025 Setups & Advanced Technical Signal Analysis - Улправда
Whale Trades: Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyMarket Growth Report & Entry and Exit Point Strategies - Улправда
Profit Recap: What sentiment indicators say about Lixte Biotechnology Holdings Inc stockJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - moha.gov.vn
Momentum Shift: Is Lixte Biotechnology Holdings Inc. stock trading at a premium valuation2025 Analyst Calls & Fast Entry Momentum Trade Alerts - Улправда
Can Lixte Biotechnology Holdings Inc. Equity Warrant stock deliver consistent earnings growthPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
What Wall Street predicts for Lixte Biotechnology Holdings Inc. Equity Warrant stock pricePortfolio Return Report & Daily Profit Maximizing Trade Tips - Улправда
Is Lixte Biotechnology Holdings Inc. Equity Warrant stock a contrarian buyTrade Risk Summary & Weekly Market Pulse Alerts - Улправда
Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesInsider Buying & Expert Approved Trade Ideas - Улправда
Will Lixte Biotechnology Holdings Inc. stock outperform tech sector in 2025Share Buyback & Stepwise Trade Execution Plans - Улправда
Why Lixte Biotechnology Holdings Inc. stock is a value investor pickJuly 2025 Trade Ideas & Scalable Portfolio Growth Ideas - DonanımHaber
Is Lixte Biotechnology Holdings Inc. Equity Warrant stock attractive for hedge funds2025 Technical Overview & Community Verified Watchlist Alerts - Улправда
Is Lixte Biotechnology Holdings Inc. (8640) stock nearing a technical breakoutQuarterly Profit Summary & Advanced Swing Trade Entry Alerts - DonanımHaber
What dividend safety rating applies to Lixte Biotechnology Holdings Inc. (8640) stockWeekly Trend Recap & AI Forecasted Entry/Exit Points - DonanımHaber
Will Lixte Biotechnology Holdings Inc. stock split again soon2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
Lixte Biotechnology shares dip after $4.3 million registered direct offering - MSN
Why Lixte Biotechnology Holdings Inc. (8640) stock is listed among top recommendationsMarket Activity Recap & Real-Time Volume Spike Alerts - Улправда
Lixte Biotechnology raises $4.3 million in registered direct offering By Investing.com - Investing.com India
Aug Sentiment: Is Lixte Biotechnology Holdings Inc. stock a buy before product launchesPortfolio Profit Report & Weekly High Potential Alerts - Улправда
Insider Trends: Will Lixte Biotechnology Holdings Inc. stock see insider buyingJuly 2025 Short Interest & Trade Opportunity Analysis Reports - Улправда
Lixte Biotechnology Launches $4.3 Million Registered Direct Offering - marketscreener.com
History Review: Will Lixte Biotechnology Holdings Inc. stock see insider buyingGap Up & Reliable Volume Spike Alerts - Улправда
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):